Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in ...
Epigenetic markers: A promising approach to predicting cardiometabolic disease risk
A new study explores how epigenetic markers—chemical modifications that influence gene activity—can help predict the risk of ...
Cancer researchers identify the 'switch' that allows intestinal cells to regenerate after injury
Researchers from the University of Colorado Cancer Center have solved a cellular mystery that may lead to better therapies ...
CRISPR Therapeutics Set To Reach Previous Heights
CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...
AHA/ASA Journals15h
XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity
BACKGROUND: Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these prevalent outcomes ...
European Medical Journal13h
The Impact of APOE-ε4 on TAU Pathology in Alzheimer’s Varies by Sex and Ethnicity
A MULTINATIONAL cohort study of 4,592 individuals has revealed significant sex and ancestry-based differences in how the APOE-ε4 gene influences Alzheimer’s disease biomarkers, with women of African ...